Contact
searchSearch
HMP Global
Login
Podcasts

Direct-to-Patient Strategies in Multiple Myeloma Care

03/13/2020

At the ACCC Annual Meeting & Cancer Center Business Summit, Anne Quinn Young, MPH, Chief Marketing and Development Officer, Multiple Myeloma Research Foundation, discussed direct-to-patient efforts in myeloma care that are poised to help improve data accumulation and ultimately provide precision therapies for patients.

 

Recent News

News
Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05/22/2026
Emily Estrada
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of...
05/22/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
FDA Approval
FDA Approves Datopotamab Deruxtecan for Patients With Triple-Negative Breast Cancer
05/22/2026
Emily Estrada
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the...
05/22/2026
Oncology
News
Ipatasertib Plus Fulvestrant and Palbociclib Shows Strong Preliminary Activity in HR-Positive, HER2-Negative Breast Cancer
05/21/2026
Stephanie Holland
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical...
05/21/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer
05/20/2026
Stephanie Holland
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial...
05/20/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Durvalumab Plus BCG Delays High-Risk Recurrence in Non-Muscle-Invasive Bladder Cancer
05/19/2026
Stephanie Holland
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC...
05/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use